Ultrasound-guided hepatic cryosurgery is a potential treatment option for select patients with unresectable tumors. Intraoperative placement of cryoprobes and monitoring of tumor freezing with ultrasonography produce complete remission in 22% to 29% of patients with unresectable metastatic colorectal tumors to the liver. Perioperative nurses should be knowledgeable about cryosurgical techniques and be prepared to participate in this innovative treatment modality to provide optimal care to surgical patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0001-2092(06)63151-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Cancer-free survival after chemotherapy, targeted immunotherapy combination with proton therapy following space making technique in a patient with cholangiocarcinoma after choledochal cyst resection.
Front Immunol
January 2025
Department of Hepatobiliary-Pancreatic-Splenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Choledochal cysts (CCs) are rare cystic dilations of the intrahepatic and/or extrahepatic bile ducts. Malignancies arising during follow-up after excision of CCs have been reported in both children and adults, with no typical time frame for malignancy development. We present a case of a patient diagnosed with CCs 36 years ago, who underwent resection and subsequently developed cancer.
View Article and Find Full Text PDFPARATHYROID CANCER: REVIEW OF UNCOMMON DISEASE.
Acta Endocrinol (Buchar)
January 2025
Baskent University, "Dr. Turgut Noyan" Teaching and Research Center, Department of General Surgery, Adana.
Parathyroid cancer is an uncommon endocrine malignancy. It has slow clinical course and low malignancy potential. It represents 1% of primary hyperparathyroidism.
View Article and Find Full Text PDFAntibody-drug conjugates in urothelial carcinoma: current status and future.
Curr Opin Urol
January 2025
Department of Medicine, Division of Hematology and Oncology, New York Presbyterian Weill Cornell Medical Center.
Purpose Of Review: Antibody-drug conjugates (ADCs) are quickly becoming frontline standard of care in many tumor types, including urothelial carcinoma. This review summarizes recent clinical investigations into the use of ADCs targeting nectin-4, trophoblast cell surface antigen-2 (Trop-2), human epidermal growth factor receptor 2 (HER-2), and other antigens in urothelial carcinoma.
Recent Findings: This review covers efficacy and toxicity data of ADCs alone and in combination with immunotherapy; mechanisms of resistance; and preclinical studies that provide biological basis for clinical approaches.
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Nat Med
January 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing, China.
Programmed cell death protein-1 (PD-1) inhibitors plus chemotherapy have been the standard of care in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma; however, the survival benefits are modest in patients with low programmed death ligand 1 (PD-L1) expression. Here we investigated the efficacy and safety of cadonilimab (PD-1/cytotoxic T lymphocyte antigen-4 (CTLA-4) bispecific antibody) plus chemotherapy as first-line treatment in G/GEJ adenocarcinoma. The prespecified interim analysis is reported here.
View Article and Find Full Text PDFTargeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight.
Drugs
January 2025
Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK.
The incidence of gastroesophageal cancers is rising, driven, in part, by an increasing burden of risk factors of obesity and gastroesophageal reflux. Despite efforts to address these risk factors, and a growing interest in methods of population screening, the bulk of these tumours are unresectable at diagnosis. In this setting, effective systemic treatments are paramount to improve survival and quality of life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!